Niraparib (Zejula) accepted for use for advanced ovarian cancer by SMC

13 August 2018

The Scottish Medicines Consortium have today announced that Niraparib (a PARP inhibitor) will be available as a maintenance treatment for women with relapsed ovarian cancer who do not have a BRCA mutation.

This enables more women in Scotland access to PARP inhibitors and allows them greater choice in how their cancer is treated.

Ovacome will continue to represent the views of our members to SMC and NICE as we advocate for broader treatment availability across the UK, for women with all types of ovarian cancer.

Read full article

Comments (0)

Please verify your action

Comment (maximum 3500 characters) (required)

Add a picture

Notify me when someone makes a comment

First name (required)

Last name (required)

Email (required)

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please tick the boxes below to opt in to receive communications from Ovacome by email, SMS, telephone, and/or post.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy.

By submitting this form you are agreeing to our terms and conditions

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.